Zoldonrasib + Daraxonrasib for Pancreatic Cancer

(RASolute 309 Trial)

This trial explores a new combination therapy using two investigational drugs, daraxonrasib and zoldonrasib, for treating pancreatic cancer. The main goal is to determine if these drugs are more effective than standard chemotherapy. Suitable candidates for this trial have advanced-stage pancreatic cancer that hasn't been treated yet and possess a specific mutation known as KRAS G12D.

As a Phase 3 trial, this study represents the final step before FDA approval, providing patients an opportunity to access potentially groundbreaking treatment.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that the combination of daraxonrasib and zoldonrasib for pancreatic cancer has a manageable safety profile. Early studies indicate that zoldonrasib, when combined with other treatments, is generally safe and well-tolerated by most patients. However, about one-third of patients taking daraxonrasib experienced serious treatment-related side effects, which can be managed.

Researchers are excited about daraxonrasib and zoldonrasib for pancreatic cancer because they offer a novel approach compared to the standard chemotherapy options like gemcitabine and nab-paclitaxel. Daraxonrasib and zoldonrasib are designed to work together to target cancer cells more precisely, potentially enhancing effectiveness and reducing side effects. Unlike traditional treatments that broadly attack rapidly dividing cells, this combination specifically disrupts cancer cell growth mechanisms, which might lead to improved outcomes for patients.

Research has shown that the combination of daraxonrasib and zoldonrasib, which participants in this trial may receive, holds promise for treating pancreatic cancer. Studies have found that 50% of patients respond positively to this treatment, with an average of 7.6 months without disease progression. In comparison, another treatment option in this trial, gemcitabine and nab-paclitaxel (a type of chemotherapy), has improved survival rates for patients with advanced pancreatic cancer. Specifically, this treatment has resulted in an average survival time of 11.1 months and a 59% increase in the number of patients living for at least one year compared to older treatments. This trial tests both treatment combinations to determine which provides better results for patients.⁶⁷⁸⁹¹⁰